Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис: http://hdl.handle.net/20.500.12188/26085
DC FieldValueLanguage
dc.contributor.authorBrezovska, Marijaen_US
dc.contributor.authorAcevska, Jelenaen_US
dc.contributor.authorNakov, Natalijaen_US
dc.contributor.authorUgrinova, Liljanaen_US
dc.contributor.authorTonic Ribarska, Jasminaen_US
dc.date.accessioned2023-03-13T11:33:46Z-
dc.date.available2023-03-13T11:33:46Z-
dc.date.issued2022-12-31-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/26085-
dc.language.isoenen_US
dc.publisherMacedonian Pharmaceutical Associationen_US
dc.relation.ispartofMacedonian Pharmaceutical Bulletinen_US
dc.titleComparative analysis of the regulatory framework for postmarketing authorization changes in EU and USAen_US
dc.typeArticleen_US
dc.identifier.doi10.33320/maced.pharm.bull.2022.68.03.098-
dc.identifier.urlhttps://bulletin.mfd.org.mk/volumes/Volume%2068_3/68_3_098.pdf-
dc.identifier.volume68-
dc.identifier.issue03-
dc.identifier.fpage205-
dc.identifier.lpage206-
item.fulltextNo Fulltext-
item.grantfulltextnone-
crisitem.author.deptFaculty of Pharmacy-
crisitem.author.deptFaculty of Pharmacy-
Appears in Collections:Faculty of Pharmacy: Journal Articles
Прикажи едноставен запис

Page view(s)

99
checked on 4.5.2025

Google ScholarTM

Проверете

Altmetric


Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.